

Free Paper Presentation [DAY 2: Friday, June 12, 2026]

Free Paper Presentation 1 [LC & Liver Failure, Autoimmune Disease 1]

Time	Abstract No.			Subject	Presenting Author	Institution/Affiliation
09:10-09:20	1	FP-01	406	Multimodal computed tomography-clinical integration for noninvasive grading of hepatic venous pressure gradient	Seul Ki Han	Yonsei University
09:20-09:30	2	FP-02	640	CT-based Spleen Volume and Laboratory Markers Differentiate Porto-Sinusoidal Vascular Disorder from Cirrhosis across Global Cohorts	Subin Heo	University of Ulsan
09:30-09:40	3	FP-03	422	Increased CD169 Expression on Peripheral Monocytes is Associated with Liver Damage in Autoimmune Hepatitis	Ga Won Han	The Catholic University of Korea
09:40-09:50	4	FP-04	973	Multimodal Clinical DILI Prediction with Quantum-derived Molecular Representation	Yujin Kim	Handong Global University
09:50-10:00	5	FP-05	237	Urgent Liver Transplantation for Acute-on-Chronic Liver Failure in National Data: Impact of Dynamic MELD Change and Donor Type on Survival	Jongman Kim	Sungkyunkwan University
10:00-10:10	6	FP-06	111	Clinical and Epidemiologic Characteristics of Autoimmune Hepatitis in Korea: Treatment Patterns and Outcomes	Soon Kyu Lee	The Catholic University of Korea
10:10-10:20	7	FP-07	648	Efficacy and Safety of Seladelpar in the Asian Subpopulation of Patients with Primary Biliary Cholangitis: Results from RESPONSE and ASSURE	Heo Jeong	Pusan National University
10:20-10:30	8	FP-08	101	Shear Wave Elastography Combined with ALBI Score Enhances Prediction of Hepatic Decompensation in Advanced Chronic Liver Disease	Jaejun Lee	The Catholic University of Korea

Free Paper Presentation 2 [Surgery, Technical Issues]

Time	Abstract No.			Subject	Presenting Author	Institution/Affiliation
09:10-09:20	1	FP-09	772	Treatment Outcomes of Liver Abscesses: Efficacy of Ultrasound-Guided Percutaneous Drainage and Surgical Interventions in a Consecutive Case Series (2019–2025)	Onlassyng Ibekenov	The National Scientific Center of Surgery Named after A. N. Syzganov, Kazakhstan
09:20-09:30	2	FP-10	214	Inflammatory and Immune Biomarkers Associated with Postoperative Outcomes after Hepatocellular Carcinoma Surgical	Lintong Simbolon	The Pranala Institute, Indonesia
09:30-09:40	3	FP-11	291	Beyond the Operating Room: Caregiver Knowledge, Attitudes, and Postoperative Recovery in Liver Disease	Hanna Rosanti	Atmajaya University, Indonesia
09:40-09:50	4	FP-12	860	A Retrospective Comparative Study on Cone Unit–Based Wide-Margin Laparoscopic Anatomical Hepatectomy and Conventional Laparoscopic Anatomical Hepatectomy in the Treatment of Hepatocellular Carcinoma	Yu Cheng	Binzhou Medical University, China
09:50-10:00	5	FP-13	687	Surgical Resection Beyond BCLC Recommendations Improves Survival in Intermediate and Advanced HCC: Nationwide Evidence from Korea	MINSEOB KIM	Seoul National University
10:00-10:10	6	FP-14	665	Clinical Feasibility of Living Donor Liver Transplantation in Patients with Acute-On-Chronic Liver Failure: An International Multicenter Study	Hye-Sung JO	Seoul National University
10:10-10:20	7	FP-15	690	Hierarchical Quantification of Surgical Workflow of Laparoscopic Left Lateral Sectionectomy Using Step–Task–Action Triplets: Experimental Analysis of the LLS48 Dataset	Han Sang PARK	Sungkyunkwan University
10:20-10:30	8	FP-16	649	Adequate Surgical Margin, Not Resection Type, Determines Long-Term Outcomes after Liver Resection for Hepatocellular Carcinoma	Boram LEE	Seoul National University

Free Paper Presentation 3 [HCC, Clinical 1]

Time	Abstract No.			Subject	Presenting Author	Institution/Affiliation
09:10-09:20	1	FP-17	107	Longitudinal elevation of IL-10 following atezolizumab plus bevacizumab is associated with favorable response and survival in advanced hepatocellular carcinoma	Soon Kyu Lee	The Catholic University of Korea
09:20-09:30	2	FP-18	917	Outcomes of Continuing Atezolizumab–Bevacizumab Beyond 2 Years in Patients with Advanced HCC: Preliminary Report of a Multicenter Retrospective Cohort Study using Landmark Analysis	Sung Won Chung	University of Ulsan
09:30-09:40	3	FP-19	118	Association of radiotherapy with atezolizumab plus bevacizumab with survival in advanced hepatocellular carcinoma	Gyung Sun Lim	Seoul National University
09:40-09:50	4	FP-20	327	Differential therapeutic effectiveness of atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma by chronic hepatitis B viral activity	Yunmi Ko	Inha University
09:50-10:00	5	FP-21	851	Refining Patient Selection for Proton Beam Therapy in Hepatocellular Carcinoma: Utility of mALBI Grade and Quantitative ALBI Score Increments	Sooyeon Sim	Sungkyunkwan University
10:00-10:10	6	FP-22	140	Genomic Profiles as Determinants of Therapeutic Efficacy in Hepatocellular Carcinoma: Towards Precision Medicine	Kwon Yong Tak	The Catholic University of Korea
10:10-10:20	7	FP-23	623	Ambient Particulate Matter Exposure and Liver Cancer Incidence and Post-Diagnosis Mortality: A Nationwide Cohort Study	Byeong Geun Song	Sungkyunkwan University

Free Paper Presentation [DAY 2: Friday, June 12, 2026]

Free Paper Presentation 4 [MASLD & ALD, Clinical]

Time	Abstract No.			Subject	Presenting Author	Institution/Affiliation
09:10-09:20	1	FP-24	153	Alcohol-Use Trajectories and Major Adverse Liver Outcomes in MetALD: A Nationwide Longitudinal Cohort Study	Dae Won Jun	Hanyang University
09:20-09:30	2	FP-25	285	Phase 3 ESSENCE Trial: Semaglutide in metabolic dysfunction-associated steatohepatitis (MASH)	Jun Yong Park	Yonsei University
09:30-09:40	3	FP-26	100	Shear Wave Elastography Is Comparable to Vibration-Controlled Transient Elastography for Predicting Liver-Related Events in a FIB-4-Based Two-Step Risk Stratification Strategy	Jaejun Lee	The Catholic University of Korea
09:40-09:50	4	FP-27	624	Distinct phenotype of cryptogenic steatotic liver disease and its unfavourable long-term outcomes including liver-related death	Hyo Young Lee	Hanyang University
09:50-10:00	5	FP-28	799	Moderate Alcohol Consumption and Liver-Related Events in MASLD: Risk Thresholds and the Impact of Cumulative Intake	Na Ryung Choi	Ewha Womans University
10:00-10:10	6	FP-29	903	Redefining the "At-Risk" Population in MASLD: A Multicenter Cross-Cohort Analysis of Liver Injury and Long-term Outcomes using Non-Invasive Tests	Han Ah Lee	Chung-Ang University
10:10-10:20	7	FP-30	155	Cost-effectiveness of resmetirom treatment for suspected 'At-Risk MASH' based on transient elastography without biopsy	Hye-Lin Kim	Sahmyook University
10:20-10:30	8	FP-31	148	Serum Osteoprotegerin Predicts Liver and Cardiometabolic Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease	Hyo Young Lee	Hanyang University

Free Paper Presentation 5 [HBV 1]

Time	Abstract No.			Subject	Presenting Author	Institution/Affiliation
13:30-13:40	1	FP-32	365	Long-Term Persistence of the Parabolic Association Between Baseline HBV DNA and Hepatocellular Carcinoma Risk After Antiviral Therapy	Hyeyeon Hong	Kyung Hee University
13:40-13:50	2	FP-33	967	Clinical Impact of Antiviral Therapy on Reducing HCC and Cirrhosis Risks in the Indeterminate Phase of Chronic Hepatitis B	Jaehong Jeong	Yonsei University
13:50-14:00	3	FP-34	951	Clinical Benefits of Antiviral Therapy in the Indeterminate Phase of Chronic Hepatitis B: A Systematic Review and Meta-Analysis	Han Ah Lee	Chung-Ang University
14:00-14:10	4	FP-35	904	NGS-Based X/Precore Genetic Heterogeneity Improves Identification of the True Immune Tolerant Phase in HBsAg-Positive Chronic Hepatitis B	Jae Mo Han	The Catholic University of Korea
14:10-14:20	5	FP-36	888	Higher Unglycosylated HBsAg Proportion May Predict Faster Decline Kinetics of HBsAg in Chronic Hepatitis B	Jeong Heo	Pusan National University
14:20-14:30	6	FP-37	602	Changes to an Active Lifestyle and Risks of Mortality and Liver-Related Events in Adults With Chronic Hepatitis B: A Nationwide Cohort Study	Myeongcheol Lee	Sungkyunkwan University
14:30-14:40	7	FP-38	635	High Treatment Adherence Reduces HCC in Cirrhosis, with Additional Benefit from TAF	Shin Yoon E	Soonchunhyang University
14:40-14:50	8	FP-39	98	Long-Term Clinical Trajectories of Chronic Hepatitis B in the Lamivudine Era: Insights from a 25-Year Real-World Study	Jaejun Lee	The Catholic University of Korea

Free Paper Presentation 6 [HCC, Basic]

Time	Abstract No.			Subject	Presenting Author	Institution/Affiliation
13:30-13:40	1	FP-40	488	Secretory Nidogen 1 Triggers the Endocytic Recycling of $\beta 5$ Integrin in Hypoxia Induced Liver Cancer Metastasis	Yaqi Xu	University of Macau, Macau
13:40-13:50	2	FP-41	686	Application of CRISPR/Cas9 Technology to Develop a Hepatocellular Carcinoma Model Using Human Primary Hepatocyte Organoids	Michael Girma MAMO	Hanyang University
13:50-14:00	3	FP-42	479	The PLD2-APP-OTC Axis Regulates Urea Cycle Activation and Tumor Growth in Hepatocellular Carcinoma	Hei-Gwon Choi	Chungnam National University
14:00-14:10	4	FP-43	322	Soluble FAP Activates STAT3 and Induces IL-6 to Sustain Cancer-Associated Fibroblast Activation via a Positive Feedback Loop in Hepatocellular Carcinoma	Deok Hwa Seo	The Catholic University of Korea
14:10-14:20	5	FP-44	637	SFRP4+ Cancer-Associated Fibroblasts Drive EMT and an Immunosuppressive Tumor Microenvironment in Hepatocellular Carcinoma	Sujin Kim	Ajou University
14:20-14:30	6	FP-45	894	Large-Scale Whole-Genome Sequencing Reveals the Mutagenic Processes Underlying Hepatocellular Carcinoma	Joonoh Lim	Inocras Inc.
14:30-14:40	7	FP-46	507	Longitudinal Single-Cell Profiling Reveals Distinct Immune Trajectories Associated with Response and Resistance to Atezolizumab-Bevacizumab in HCC	Myung Ji Goh	Sungkyunkwan University
14:40-14:50	8	FP-47	809	Immune Cell Profiling and Real-World Long-Term Efficacy of Adjuvant Cytokine-Induced Killer Cell Therapy for Hepatocellular Carcinoma	Hyunjae Shin	Seoul National University

Free Paper Presentation [DAY 2: Friday, June 12, 2026]

Free Paper Presentation 7 [MASLD & ALD, Basic]

Time	Abstract No.			Subject	Presenting Author	Institution/Affiliation
13:30-13:40	1	FP-48	123	A Stage Specific NETs-Related Signature in Alcoholic Steatohepatitis: From Molecular Subtyping to Therapeutic Vulnerabilities	Wei Gao	The First Affiliated Hospital of Guangxi Medical University, China
13:40-13:50	2	FP-49	603	Single-cell transcriptomic profiling reveals stage-specific reprogramming of peripheral NK cells from compensatory hyperactivation to terminal exhaustion during alcohol-associated liver disease progression	Young-Sun Lee	Korea University
13:50-14:00	3	FP-50	305	Blocking the Gut–Liver IgA Axis Attenuates Macrophage-Mediated Inflammation and Injury in Alcohol-Associated Liver Disease	Min Gu Kim	The Catholic University of Korea
14:00-14:10	4	FP-51	625	Spatial Transcriptomics Reveals Macrophage–Fibroblast Crosstalk as a Driver of MASH Fibrosis and Guides CD47-Engineered Extracellular Vesicle Therapy	Young-Sun Lee	Korea University
14:10-14:20	5	FP-52	908	Hepatic CSE Deficiency Impairs Systemic Glutathione Homeostasis and Promotes Liver–Kidney Redox Imbalance in Obesity	SE YOUNG JANG	Kyungpook National University
14:20-14:30	6	FP-53	149	The Single-Cell Landscape of MASLD-Specific Liver Sinusoidal Endothelial Cell Subclusters	DAE WON JUN	Hanyang University
14:30-14:40	7	FP-54	660	Metabolic Stress Transforms DNA Damaged Biliary Epithelial Cells into Hepatocellular Carcinomas	Won Hee Lee	Yonsei University
14:40-14:50	8	FP-55	790	Aging-Associated Clonal Hematopoiesis in TET2-Mutant HSCs Drives Myeloid Expansion and Accelerates Liver Inflammation and Fibrosis in MASH	Hanna Lee	Kangwon National University

Free Paper Presentation [DAY 3: Saturday, June 13, 2026]

Free Paper Presentation 8 [MASLD, Clinical]

Time	Abstract No.			Subject	Presenting Author	Institution/Affiliation
09:10-09:20	1	FP-56	926	Proposal of a Body Mass Index-Based Subclassification for Patients with Metabolic Dysfunction-associated Steatotic Liver Disease with Increased Alcohol Intake	Norihiro Imai	Nagoya University, Japan
09:20-09:30	2	FP-57	797	Serum free triiodothyronine to free thyroxine ratio and risk of developing metabolic dysfunction-associated steatotic liver disease: A large-scale cohort study	Hyunwoo Oh	Sungkyunkwan University
09:30-09:40	3	FP-58	94	Dynamic Transitions in Steatotic Liver Disease Subtypes and Risk of Liver-related Events: A Nationwide Cohort Study	Yewan Park	Kyung Hee University
09:40-09:50	4	FP-59	636	Development and Validation of M-SLD: A Novel Noninvasive Model for Steatotic Liver Disease Referenced Against Histology and MRI-PDFF	Hyo Jin Nam	University of Ulsan
09:50-10:00	5	FP-60	312	Metabolic–Alcohol Spectrum of Steatotic Liver Disease and Risk of Incident Gout: A Multi-National Cohort Study in Korea, Japan, and the United Kingdom	Yeo Wool Kang	Dong-A University
10:00-10:10	6	FP-61	694	Liver-Related Outcomes in Diabetes-Associated MASLD with Low Fatty Liver Index: a Nationwide Cohort Study	Moon Haeng Hur	Seoul National University
10:10-10:20	7	FP-62	596	Potential Influence of PNPLA3 Genotype on Semaglutide Response in Metabolic Dysfunction–Associated Steatotic Liver Disease: Real-world data in Korean cohort	Hee Sun Cho	The Catholic University of Korea
10:20-10:30	8	FP-63	51	Liver fibrosis burden and ECG-detected incident atrial fibrillation in metabolic dysfunction–associated steatotic liver disease	Tom Ryu	Soonchunhyang University

Free Paper Presentation 9 [HCC, Clinical 2]

Time	Abstract No.			Subject	Presenting Author	Institution/Affiliation
09:10-09:20	1	FP-64	628	A Mechanism-Informed Six-Gene Prognostic Signature of Hepatocellular Carcinoma Derived from the Multi-Target Anti-Tumor Mechanism of Icaritin	Mei Yao	Guangxi Medical University, China
09:20-09:30	2	FP-65	133	Comparative Effectiveness of Atezolizumab–Bevacizumab vs. Durvalumab–Tremelimumab in Unresectable HCC: A Systematic Review and Novel Machine Learning-Based Indirect Meta-Analysis	Ji Won Han	The Catholic University of Korea
09:30-09:40	3	FP-66	897	Synergistic Efficacy of Radiation Therapy Combined with Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma with Vp4 Portal Vein Tumor Thrombosis: A Multicenter Study	Young Joo Park	Pusan National University
09:40-09:50	4	FP-67	1003	Development of an Early Prediction Model for Atezolizumab–Bevacizumab Treatment Response in Patients with Advanced Hepatocellular Carcinoma: An Interim analysis of a Prospective Cohort Study	Minsuk David Kim	Seoul National University
09:50-10:00	5	FP-68	130	PNPLA3, but not a five-variant polygenic risk score, predicts hepatocellular carcinoma in Korean MASLD	Jaeeun Lee	The catholic University of Korea
10:00-10:10	6	FP-69	419	Overcoming the Limitations of GALAD: SeeLiver Enables Superior Early and AFP-Negative HCC Detection	Je-Hyun Baik	Seegene Medical Foundation
10:10-10:20	7	FP-70	439	In-Context Learning-Based Prediction of 5-Year Hepatocellular Carcinoma Risk in Chronic Hepatitis B	Soyeon Park	Handong Global University
10:20-10:30	8	FP-71	650	The Obesity Paradox in Hepatocellular Carcinoma: Insights from Continuous and Interaction-Based Analyses of Body Mass Index after Hepatic Resection	Boram LEE	Seoul National University

Free Paper Presentation [DAY 3: Saturday, June 13, 2026]

Free Paper Presentation 10 [HBV & HCV]

Time	Abstract No.			Subject	Presenting Author	Institution/Affiliation
09:10-09:20	1	FP-72	782	RE-LIVE Study (Re-Linkage to Pan-Viral Hepatitis): Interim Results from a Multicenter Observational Study on Care Engagement in Chronic Viral Hepatitis	Jae Hyun Yoon	Chonnam National University
09:20-09:30	2	FP-73	644	Association Between Chronic Hepatitis C and Extrahepatic Malignancies: A Nationwide Cohort Study Short Title: HCV and Extrahepatic Malignancies	Dong Hyeon Lee	Seoul National University
09:30-09:40	3	FP-74	890	Impact of Hepatitis C Virus Treatment on the Risk of Cardiovascular Disease: A Nationwide Population-Based Cohort Study in South Korea	Min Kyung Park	Seoul National University
09:40-09:50	4	FP-75	414	Outcomes of Direct-Acting Antiviral Agents in Chronic Hepatitis C Patients with Pre-existing HCC	Hyun Young Woo	Pusan National University
09:50-10:00	5	FP-76	705	Moderate HBV DNA levels are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B: A systematic review and meta-analysis	Jeong-Ju Yoo	Soonchunhyang University
10:00-10:10	6	FP-77	646	HBV Core-Related Antigen Levels Correlate with Quantitative HBsAg Levels Regardless of HBeAg Status and Antiviral Therapy	Soon Kyu Lee	The Catholic University of Korea
10:10-10:20	7	FP-78	270	Distinct Virological Features and Quasispecies Dynamics in Advanced Fibrosis by HBeAg status in Chronic Hepatitis B with normal or mildly elevated ALT	Hye Seon Kim	The Catholic University of Korea
10:20-10:30	8	FP-79	136	Incidence and Risk Stratification of Hepatitis B Reactivation in Patients Receiving Anti-CD38 Monoclonal Antibody Therapy	Kwon Yong Tak	The Catholic University of Korea

Free Paper Presentation 11 [Liver Transplantation 1]

Time	Abstract No.			Subject	Presenting Author	Institution/Affiliation
09:10-09:20	1	FP-80	710	Characterization of CCR8+ Regulatory T Cells as a Key Driver of Tumor Recurrence after Liver Transplantation for Hepatocellular Carcinoma	Ruidong DING	Affiliated Hospital of Qingdao University, China
09:20-09:30	2	FP-81	722	Graft Weight, Not GRWR, Predicts Recipient Survival in Living Donor Liver Transplantation: Implications for Donor Pool Expansion from a Stratified Analysis of 2,506 Cases	Selvakumar NAGANATHAN	Max Healthcare Institute, India
09:30-09:40	3	FP-82	372	Single-Cell and Bulk RNA Sequencing Reveal MCL1 as a Key Regulator of Mitochondrial Function in Liver Ischemia-Reperfusion Injury	Xianxiang Chen	The First Affiliated Hospital of Guangxi Medical University, China
09:40-09:50	4	FP-83	658	Integration of a Pre-transplant 15-protein Serum Proteomic Signature Predicts Recurrence after Liver Transplantation for HCC: A Multicenter KOTRY Registry Study	Sung Won Chung	University of Ulsan
09:50-10:00	5	FP-84	656	Donor Complications in Modern LDLT	Gayoung KIM	Seoul National University
10:00-10:10	6	FP-85	132	Optimal Duration of Endoscopic Biliary Stenting After Living Donor Liver Transplantation: A Machine Learning Risk Stratification Analysis	Ji Won Han	The Catholic University of Korea
10:10-10:20	7	FP-86	391	Development and validation of a LI-RADS-based competing risk survival models for liver transplant recipients with HCC	Yeongseok Hwang	Hanyang University
10:20-10:30	8	FP-87	695	Artificial Intelligence-Driven Preoperative Risk Stratification for Early Allograft Failure in Living Donor Liver Transplantation	Dae-Hyeon WON	University of Ulsan

Free Paper Presentation 12 [HBV 2]

Time	Abstract No.			Subject	Presenting Author	Institution/Affiliation
13:50-14:00	1	FP-88	798	Combination Therapy with Toll-like receptor 7 Agonist and Programmed Death Ligand 1 Antibody Restores HBV-Specific CD8+T Cells in Virally suppressed Chronic Hepatitis B	Yuying Chen	Huazhong University, China
14:00-14:10	2	FP-89	71	High Viral Suppression In Chronic HBV Infection Subjects With Pevifoscorvir Sodium Monotherapy	Man-Fung Yuen	The University of Hong Kong, Hong Kong
14:10-14:20	3	FP-90	120	Reduction of HBV Antigens Observed After 96 Weeks of 300 mg Pevifoscorvir Sodium Monotherapy is Sustained During Long-term Follow-up	Lung Yi Mak	The University of Hong Kong, Hong Kong
14:20-14:30	4	FP-91	905	Exposure to tenofovir alafenamide and tenofovir disoproxil fumarate and the risk of hepatocellular carcinoma	W. Ray Kim	Mayo Clinic, USA
14:30-14:40	5	FP-92	583	Early Antiviral Therapy and the Hepatocellular Carcinoma Incidence in Chronic Hepatitis B Patients With Normal Alanine Aminotransferase Levels: A Prospective Phase II Study	Dong Hyun SHIN	Sungkyunkwan University
14:40-14:50	6	FP-93	549	Association Between Metabolic Dysfunction-associated Steatotic Liver Disease and Hepatocellular Carcinoma Risk in Adults with Chronic Hepatitis B: A Nationwide Population-based Cohort Study	Jia-Ling Wu	E-Da Hospital, Taiwan
14:50-15:00	7	FP-94	849	Kinetic Breakpoints and Immune Remodeling During Quantitative HBsAg Decline in Chronic Hepatitis B	Sung Won Chung	University of Ulsan
15:00-15:10	8	FP-95	896	Comparative Risk of Hepatocellular Carcinoma Among Oral Antiviral Agents in Patients with Chronic Hepatitis B: A Systematic Review and Network Meta-Analysis	Heechul Nam	The Catholic University of Korea

Free Paper Presentation [DAY 3: Saturday, June 13, 2026]

Free Paper Presentation 13 [LC Basic & Liver Failure, Autoimmune Disease 2]

Time	Abstract No.			Subject	Presenting Author	Institution/Affiliation
13:50-14:00	1	FP-96	862	How hepatitis C screening entered South Korea's National Health Screening Program: a policy analysis using Kingdon's Multiple Streams Framework	Seunghyun Lewis Kwon	Korea Disease Control and Prevention Agency
14:00-14:10	2	FP-97	613	Heterogeneous Associations of Clonal Hematopoiesis With Liver Disease Outcomes: A Two-Cohort Study	Hyunjae Shin	Seoul National University
14:10-14:20	3	FP-98	523	xCT-Dependent Cysteine Metabolism Sustains Pro-Resolving TREM2+ MDMs in Liver Fibrosis	Kyurae Kim	KAIST
14:20-14:30	4	FP-99	521	Cortisol metabolic reprogramming in liver cirrhosis with diagnostic and prognostic implications	Eun Ju Cho	Seoul National University
14:30-14:40	5	FP-100	910	Targeting DNA stress response as a synthetic lethal strategy for activated hepatic stellate cells	Eui Jin Lee	Seoul National University
14:40-14:50	6	FP-101	105	Impact of Cardiometabolic Risk Factors and Alcohol Consumptions in Decompensated Liver Cirrhosis	Keungmo Yang	The Catholic University of Korea
14:50-15:00	7	FP-102	887	Efficacy of Albumin Therapy in Patients with Decompensated Cirrhosis: A Systematic Review and Meta-Analysis	Seul Ki Han	Yonsei University Wonju
15:00-15:10	8	FP-103	711	Comparative Effectiveness of Antibiotic Prophylaxis for Spontaneous Bacterial Peritonitis in Patients with Cirrhosis: A Network Meta-analysis of Randomized Trials	Moon Haeng Hur	Seoul National University

Free Paper Presentation 14 [Liver Transplantation 2]

Time	Abstract No.			Subject	Presenting Author	Institution/Affiliation
13:50-14:00	1	FP-104	294	Health and Economic Costs of Liver Disease in Southeast Asia: Implications for Transplant and Surgical Planning	Hanna Rosanti	Atmajaya University, Indonesia
14:00-14:10	2	FP-105	781	Correlation of Early Post-Operative Outcomes on Graft Weight Variations in Right Lobe Recipient Living-Donor Liver Transplantation: A Single Center Retrospective Study	Meynard Keynes DELA CRUZ	Max Superspecialty Hospital, India
14:10-14:20	3	FP-106	734	Randomized Trial Comparing Postoperative Outcomes of PTFE vs. Polyethylene Terephthalate Grafts in Neo-Middle Hepatic Vein Reconstruction for Right Lobe Living Donor Liver Transplantation	Mrunal AWALEKAR	Amrita Institute of Medical Sciences, India
14:20-14:30	4	FP-107	764	Sequential NRP and Hypothermic versus Normothermic Ex-Situ Perfusion in Extended Criteria DCD Liver Transplantation: A Randomized Prospective Trial	Lorenzo PETAGNA	Azienda Ospedaliera Universitaria Pisana, Italy
14:30-14:40	5	FP-108	657	Long-Term Changes in Liver Stiffness after Living Donor Hepatectomy: The Impact of Metabolic Vulnerability	Sukmin GWON	Sungkyunkwan University
14:40-14:50	6	FP-109	682	Translational Application of Acellular Dermal Matrix for Hepatic Vein Reconstruction in LDLT: From Bench Validation to Clinical Efficacy	Seok-Hwan KIM	Chungnam National University
14:50-15:00	7	FP-110	688	Initial Extreme High Titer Does Not Worsen Outcomes When Adequate Desensitization Is Performed in ABO-Incompatible Living Donor Liver Transplantation	Sung-Min KIM	University of Ulsan
15:00-15:10	8	FP-111	928	Sex Disparities in Liver Transplant Prioritization Across Scoring Systems: A Korean Multicenter Cohort Study	Jeayeon Park	Ajou University

